amazon one medical glp-1 Amazon's rolls out program Amazon One Medical launches national

Expanding GLP-1 pipeline globally Amgen Inc

Compare semaglutide vs tirzepatide for weight loss in Jacksonville FL

The Gallup Poll found that overall, use of semaglutide medicines or liraglutides doubled from nearly 6% in the first quarter of 2024 to over 12% in Q2 + Q3 in 2025

A new study finds cognitive decline in patients taking GLP-1 medications for longer than 10 years, yet researchers say it may be the result of those patients living longer than their peers.

To address this growing global challenge, the World Health Organization (WHO) has developed a guideline on the use of glucagon-like peptide-1 (GLP-1) based therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for adults living with obesity.Join us at the virtual launch event in a webinar hosted by WHO in collaboration with the Journal of the American Medical Association (JAMA) on 1 December 2025 at 16:00 CET

report here on a GIPR antagonist conjugated to GLP-1 analogues that reduces body weight and improves metabolic markers in preclinical and phase 1 clinical settings.